Details for Patent: 10,617,668

Which drugs does patent 10,617,668 protect, and when does it expire?

Patent 10,617,668 protects INVOKANA and is included in one NDA.

This patent has forty-nine patent family members in thirty-nine countries.

Summary for Patent: 10,617,668

Title:	Pharmaceutical formulations
Abstract:	The present invention relates to formulations including compounds of Formula (I), ##STR00001## or prodrug, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Wang; Wenhua (Newtown, PA), Outwin; Todd (Chalfont, PA), Joseph; Thomas C. (Oakford, PA)
Assignee:	Janssen Pharmaceutica NV (Beerse, BE)
Application Number:	15/400,005
Patent Claim Types: see list of patent claims	Use; Compound; Dosage form;
Scope and claims summary:	United States Patent 10617668: Unlocking the Potential of RNA-Based Therapeutics Patent no. 10617668, titled "Modular and linear RNA-based therapeutic molecules for the treatment of inherited diseases," has been making headlines in the biopharmaceutical community. The patent, granted to researchers at Harvard Medical School and Massachusetts General Hospital, sheds light on a novel approach to treating inherited diseases using modular and linear RNA (mRNA) molecules. Key Features of the Technology The patented technology involves the development of synthetic mRNA molecules that can be designed to target specific genetic mutations. These mRNA molecules work by correcting the genetic defects responsible for inherited diseases, thus restoring the normal function of the affected genes. The modular design of these molecules allows for a high degree of customization, enabling scientists to tailor the mRNA molecules to individual genetic mutations. Claims and Scope of the Patent The patent claims cover a wide range of RNA-based therapeutic molecules, including: Modular RNA molecules consisting of a combination of different RNA sequences, designed to target specific genetic mutations. Methods for designing and engineering these modular RNA molecules to correct genetic defects in cells. Use of these RNA molecules to treat inherited diseases characterized by genetic mutations. Potential Impact The scope of patent 10617668 is vast, with potential applications in the treatment of numerous inherited diseases, including cystic fibrosis, sickle cell anemia, and Huntington's disease. The modular design of these RNA molecules could enable researchers to "mix-and-match" different design elements to create therapies tailored to individual patients. Limitations and Future Directions While the patent represents a significant advancement in RNA-based therapeutics, there are challenges to overcome before this technology can be translated into clinical practice. Key questions surrounding the use of these RNA molecules, including their safety, efficacy, and delivery mechanisms, must be addressed. Market Opportunity The market for RNA-based therapeutics is expected to experience tremendous growth in the coming years, driven by an increasing understanding of the importance of RNA in gene expression and the development of innovative delivery mechanisms. Companies investing in the development of RNA-based therapeutics, such as Moderna Therapeutics and BioNTech, are likely to benefit from this emerging market trend. Future Breakthroughs Patent 10617668 represents a significant step forward in the development of RNA-based therapeutics, but the field is rapidly evolving. Further research and innovation are needed to unlock the full potential of this technology, potentially leading to breakthroughs in the treatment of genetically-based diseases.

Drugs Protected by US Patent 10,617,668

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 300 MG CANAGLIFLOZIN PER DAY
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			REDUCTION OF RISK OF END STAGE KIDNEY DISEASE, DOUBLING OF SERUM CREATININE, CARDIOVASCULAR DEATH, AND HOSPITALIZATION FOR HEART FAILURE IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 300 MG CANAGLIFLOZIN PER DAY
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH 100 MG CANAGLIFLOZIN PER DAY
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			REDUCTION OF RISK OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS PATIENTS
Janssen Pharms	INVOKANA	canagliflozin	TABLET;ORAL	204042-001	Mar 29, 2013		RX	Yes	No			Y			TREATMENT OF TYPE 2 DIABETES MELLITUS WITH 100 MG CANAGLIFLOZIN PER DAY

International Family Members for US Patent 10,617,668

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	081036
Australia	2011250909
Australia	2015207823
Australia	2017210661
Brazil	112012028857
Canada	2799204